

ARUN R. MAHANKALI SRIDHAR, MD, MPH

Assistant Professor, Section of Electrophysiology, Division of Cardiology, University of Washington, Seattle

OUSSAMA WAZNI, MD

Cardiac Electrophysiology and Pacing, Department of Cardiovascular Medicine, Heart and Vascular Institute, Cleveland Clinic; Professor, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH

AYMAN A. HUSSEIN, MD

Cardiac Electrophysiology and Pacing, Department of Cardiovascular Medicine, Heart and Vascular Institute, Cleveland Clinic; Clinical Assistant Professor, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH

Ablation of atrial fibrillation: Facts for the referring physician

ABSTRACT

Radiofrequency ablation has become a safe and effective treatment for atrial fibrillation. We believe that referral to an electrophysiologist for consideration of ablation may allow for better rhythm control and outcomes by altering the natural history of atrial fibrillation progression.

KEY POINTS

Atrial fibrillation is increasing in prevalence with the aging of the US population and is associated with worsening quality of life and increased risk of stroke, heart failure, and death.

Atrial fibrillation results in adverse atrial remodeling and fibrosis, eventually leading to persistence of the arrhythmia and making rhythm control difficult.

Catheter ablation has evolved to be a safe procedure with technologic advancements, especially in experienced tertiary care centers.

The primary aim of atrial fibrillation ablation is to reduce symptoms and improve quality of life. In theory, it could also decrease the risk of stroke, heart failure, and death, but these outcomes have not been systematically evaluated in a large randomized controlled trial.

A 64-YEAR-OLD MAN with hypertension but without known structural heart disease presents for a second opinion on management of his atrial fibrillation. The condition was first diagnosed at age 38, when he experienced palpitations and shortness of breath on exertion; at times he also experienced decreased endurance and fatigue without overt palpitations. At first, these episodes occurred about twice a year, and the patient was managed with a beta-blocker for rate control and an oral anticoagulant.

Over the past 10 years, the episodes have become more frequent and longer-lasting and have required frequent cardioversions. He was given flecainide for rhythm control but continued to have frequent episodes, and so about 1 year ago he was switched to amiodarone, which controlled his rhythm better. However, after reading about side effects of amiodarone, he decided to seek a second opinion.

He was evaluated by our team and eventually underwent radiofrequency ablation. During the procedure, he was noted to have diffuse scarring and fibrosis of his left atrium, and afterward he continued to require antiarrhythmic drugs to maintain sinus rhythm.

Should he have been referred sooner? What factors should primary care physicians consider when referring a patient with atrial fibrillation for ablation?

■ THE EPIDEMIC OF ATRIAL FIBRILLATION

Atrial fibrillation is a large and growing public health problem. In 2010, it was estimated to affect 2.7 to 6.1 million people in the United States, and with the rapid aging of our population, its prevalence is expected to rise to between 5.6 and 12 million by 2050.¹⁻³ It is associated with significant morbidity, poor quality




Figure 1. Atrial fibrillation is currently thought to arise from focal triggers, many of which are located in the pulmonary veins, and to be maintained by an abnormal substrate, ie, scarring and fibrosis of the left atrium.

Chowdhury P, Lewis WR, Schweikert RA, Cummings JE. Ablation of atrial fibrillation: what can we tell our patients? *Cleve Clin J Med* 2009; 76(9):543-550. doi:10.3949/ccjm.76a.08091

Atrial fibrillation is expected to increase in prevalence with the aging of the population

of life, and increased risk of death, heart failure, stroke, and cognitive impairment.

The number of new cases per year has increased over the years despite research and preventive measures, which may reflect aging of the population and increased survival rates in patients with cardiovascular or comorbid conditions.^{1,4}

Thus, atrial fibrillation is one of the most common cardiovascular conditions encountered by primary care physicians and cardiologists, putting them at the forefront of its management. Proper treatment in its early stages and referral to a specialist for advanced management may alter its natural history and improve clinical outcomes.

■ HOW DOES ATRIAL FIBRILLATION ARISE AND PERSIST?

Much is still unknown about the pathogenesis of atrial fibrillation, but considerable progress has been made in the past few decades, opening the door for clinical ablative strategies.

Multiple wavelet hypothesis

Until the late 1980s, the most widely accepted conceptual mechanism of atrial fibrillation was the multiple wavelet hypothesis developed by Moe et al.⁵ According to this hypothesis, atrial fibrillation begins with multiple independent wavelets occurring simultaneously and spreading randomly throughout both atria, and it persists if there are a minimum number of coexisting wavelets, increased atrial mass, and heterogeneous conduction delays across the atrial tissue.

The surgical maze procedure, in which a series of incisions arranged in a maze-like pattern is created in the left atrium, was predicated on this model. The theory was that these surgical lesions would compartmentalize the atria into discrete electrical segments and thereby reduce the number of circulating random wavelets.^{6,7}

However, experimental and clinical studies suggest that although randomly propagating wavelets can contribute to maintaining atrial fibrillation, focal triggers are noted in most cases.

Focal triggers

In 1997, Jaïs et al⁸ observed that atrial fibrillation is often triggered by a rapidly firing ectopic focus and that ablation of that focus can eliminate it. These ectopic foci are often found at or near the ostia of the pulmonary veins or near the superior vena cava.^{8,9} It is now well established that ectopic foci in the pulmonary veins are crucial triggers that initiate atrial fibrillation.

Trigger-and-substrate theory

Currently, the most widely accepted theory is that atrial fibrillation requires both a trigger and a susceptible substrate (**Figure 1**). Triggers consist of rapidly firing foci, most commonly located in the pulmonary veins but also in the superior vena cava, posterior wall of the left atrium, the vein and ligament of Marshall, the coronary sinus, and the left atrial appendage.

The substrate for maintaining atrial fibrillation consists of an abnormal left atrium with heterogeneous fibrosis (scarring) and conduction delays. Any heart disease that increases left atrial pressure could lead to atrial dilation and remodeling, which could be substrates for atrial fibrillation. Extensive atrial remodeling and scarring are associated with progression




FIGURE 2. Ablation vs medical management of atrial fibrillation. Most electrophysiologists in our institution use this general approach to decision-making.

The current theory is that atrial fibrillation requires both a trigger and a susceptible substrate

and persistence of atrial fibrillation and make rhythm control more challenging.

Atrial fibrillation begets atrial fibrillation

As shown in the case above, over time, paroxysmal atrial fibrillation often progresses to persistent and long-standing atrial fibrillation if not aggressively managed initially.

In 1972, Davies and Pomerance¹⁰ performed 100 autopsies and found that the people who had had atrial fibrillation for longer than 1 month had lost muscle mass in the sinus node and internodal tract, and their atria were dilated. The study introduced the concept that atrial fibrillation itself causes pathologic changes in the atrium.

Wijffels et al,¹¹ in an experiment in goats, showed that atrial fibrillation produced by rapid bursts of atrial pacing was initially paroxysmal. However, as they continued to induce atrial fibrillation over and over again, it lasted progres-

sively longer until it would persist for more than 24 hours. Thus, in a relatively short time, the atria went from supporting paroxysmal fibrillation to supporting persistent fibrillation.

Atrial fibrillation leads to electrophysiologic and anatomic remodeling in the atrium, which leads to a shorter action potential duration and a shorter refractory period. This in turn makes it easier for atrial fibrillation to persist.¹²

Because atrial fibrillation tends to progress, intervening early may improve its outcomes. Early ablation has been shown to improve the chances of staying in sinus rhythm in both paroxysmal and persistent atrial fibrillation.¹³⁻¹⁵

■ CATHETER ABLATION OF ATRIAL FIBRILLATION

The goal of ablation is to prevent atrial fibrillation by eliminating the trigger that initiates it, altering the arrhythmogenic substrate, or both.




Figure 3. Radiofrequency ablation of atrial fibrillation.

Chowdhury P, Lewis WR, Schweikert RA, Cummings JE. Ablation of atrial fibrillation: what can we tell our patients? *Cleve Clin J Med* 2009; 76(9):543-550. doi:10.3949/ccjm.76a.08091

Over time, paroxysmal atrial fibrillation often progresses to persistent if not aggressively managed initially

Pulmonary vein isolation

The most common ablation strategy is to electrically isolate the pulmonary veins by creating circumferential lesions around their antra. This creates a nonconducting rim of scar tissue, electrically disconnecting the pulmonary veins from the atrium.

Ablation outside of the pulmonary veins

Because recurrence rates are high in patients with persistent atrial fibrillation who undergo pulmonary vein ablation alone, the search continues for adjunctive strategies to improve outcomes. Although these strategies have a sound rationale based on experimental data and anecdotal evidence in humans, they have not yet been convincingly shown to be helpful in large clinical studies. Nonetheless, it is possible that more extensive substrate ablation—atrial “debulking”—could improve outcomes by reducing the amount of tissue that can fibrillate.

Linear ablation. Creating lines of ablation (as in the maze procedure) isolates different segments of the left atrium. Often, these lines

are created along the roof of the left atrium between the right and left upper pulmonary veins and from the mitral valve to the left inferior pulmonary vein. The benefit of linear ablation has not been proven, and gaps in such lines may introduce atrial flutter.

Triggers not in the pulmonary veins. Common sites of nonpulmonary vein triggers include the posterior wall of the left atrium, the superior vena cava, the coronary sinus, and along the ligament of Marshall. Provocative maneuvers such as isoproterenol infusion can help find those triggers, which can then be ablated. A limitation is that there is no protocol proven to reproducibly elicit triggers.

Complex fractionated atrial electrograms are areas in the atrium with highly fractionated, low voltage potentials. They may be critical sites of substrate for atrial fibrillation, and many electrophysiologists target them in patients with persistent atrial fibrillation. But despite initial enthusiasm, doing so has not resulted in better outcomes in persistent atrial fibrillation.

Rotors. Animal studies have shown that atrial fibrillation can be triggered or maintained by localized sources of organized reentrant circuits (rotors) or focal impulses. Recent studies have shown that these electrical rotors and focal sources could potentially be mapped and ablated in humans. But positive results in initial reports have not been reproduced, and this remains an area of controversy.

Our practice. We isolate the pulmonary veins with antral ablations, ablate the posterior wall, and extend the ablation toward the septum and inferior to the right pulmonary veins, with good long-term outcomes.¹⁴ The rationale behind ablating the posterior wall is that it shares embryologic origins with the pulmonary veins and may be a common source of triggers in atrial fibrillation.

We do not routinely create empiric ablation lines in the left or right atrium unless the patient has atrial flutter. Empiric ablation lines have not been convincingly shown to provide additional benefit compared with our extensive ablation approach, which involves the posterior wall. Empiric ablation of the appendage or coronary sinus is typically reserved for repeat ablation in patients with recurrent persistent atrial fibrillation.

RATIONALE FOR TREATING ATRIAL FIBRILLATION WITH ABLATION

To control symptoms

At this time, the primary aim of atrial fibrillation ablation is to reduce symptoms and improve quality of life. In theory, ablation could also decrease the risk of stroke, heart failure, and death. However, these outcomes have not been systematically evaluated in any large randomized controlled trial.

To control rhythm and improve survival

Randomized controlled trials of rhythm vs rate control of atrial fibrillation¹⁶⁻¹⁸ have failed to demonstrate that restoring sinus rhythm is associated with better survival. All of these trials used antiarrhythmic drugs for rhythm control. However, nonrandomized studies^{19,20} showed that maintaining sinus rhythm is associated with a significant reduction in mortality rates, whereas the use of antiarrhythmic drugs increased mortality risk.

This suggests that the beneficial effect of restoring sinus rhythm may be offset by adverse effects of antiarrhythmic drugs, and if rhythm control could be achieved by a method other than antiarrhythmic drug therapy, it may be superior to rate control. On the other hand, these data may be affected by residual confounding. This topic deserves further research, but maintaining sinus rhythm is typically preferred whenever possible.

Discontinuing anticoagulation is not a goal at this time

Retrospective studies have reported a low risk of stroke in patients who discontinue anticoagulation several months after undergoing atrial fibrillation ablation.²¹⁻²³ However, atrial fibrillation can recur, and risk of stroke increases with age.

Therefore, guidelines²⁴ still recommend continuing anticoagulation after ablation. Generally, we do not offer ablation with a goal of discontinuing anticoagulation. That said, stopping anticoagulation may be considered after long-term suppression of paroxysmal atrial fibrillation on a case-by-case basis in patients deemed to be at low risk. Left atrial appendage closure devices may eventually allow concomitant atrial fibrillation ablation and closure of the appendage, so that anticoagu-




Figure 4. Fluoroscopic view of radiofrequency ablation. The PentaRay catheter is used to acquire data for 3-dimensional mapping (Figure 7).

lation could then be stopped. This remains a topic of investigation.

Who should be considered for ablation?

There are no absolute age or comorbidity contraindications to ablation. Everyone who has atrial fibrillation deserves, in our opinion, a referral to the electrophysiology clinic.

The decision to pursue ablation as opposed to trying drugs is nuanced, and needs a proper discussion with an electrophysiologist. The discussion of risks, benefits, and alternatives and the shared decision-making process before a patient undergoes ablation is the most time-consuming process in our clinic. **Figure 2** shows our approach to deciding between ablation and medical management of atrial fibrillation.

PROCEDURAL CONSIDERATIONS

Atrial fibrillation ablation is most often performed by electrophysiologists using a minimally invasive endovascular approach. The patient can be under either moderate sedation or general anesthesia; we prefer general anes-




Figure 5. A balloon catheter lodged in the ostium of one of the pulmonary veins to create a circumferential cryothermal lesion, electrically isolating the pulmonary vein.

Natale A. Radiofrequency ablation of the pulmonary veins: can it stop atrial fibrillation at its source? *Cleve Clin J Med* 2001; 68(1):17–23. PMID:11204363

The decision to stop anticoagulation is based on stroke risk as assessed by the CHA₂DS₂-VASc score and not on the success of the ablation

thesia for patient comfort, safety, and efficacy.

The catheter is inserted into the femoral vein and advanced into the right atrium. The interatrial septum is punctured under fluoroscopic and intracardiac echocardiographic guidance. Once the catheter is inside the left atrium, the antra of the pulmonary veins are located, and antral ablation is performed to electrically isolate the pulmonary veins from the atrial myocardium (**Figure 3, Figure 4**).

We use an electrogram-based technique to target and eliminate electrical potentials and ensure continuity of ablation sets, with additional guidance by 3-dimensional cardiac mapping systems and intracardiac echocardiography. We also use contact force-sensing catheters to ensure catheter-tissue contact during ablation and to avoid excessive contact, which may enhance the safety of the procedure.

Energy: Hot or cold

Two types of energy can be used for ablation:

Radiofrequency energy (low voltage, high frequency—30 kHz to 1.5 MHz) is delivered to the endocardial surface via a point-source catheter. The radiofrequency energy produces controlled, focal thermal ablation.

Cryothermal energy, ie, extreme cold, is delivered by a balloon catheter to create cir-

cumferential lesions around the pulmonary vein antrum (**Figure 5**).

In a randomized trial,²⁵ these ablation technologies were shown to be equivalent for preventing recurrences of atrial fibrillation. We use both in our practice. The choice depends primarily on the planned ablation set, given that balloon cryoablation can achieve antral isolation of the pulmonary veins but allows little or no substrate modification.

Improved ablation technology

Intracardiac echocardiography, performed with an endovascular catheter in the right atrium, directly displays the interatrial septum, left atrium, pulmonary veins, ablation catheter, and catheter-tissue interface during ablation (**Figure 6**). It is used to guide transseptal puncture, assess tissue-catheter contact during ablation, and monitor for complications. We also use it in balloon cryothermal ablation to ensure proper occlusion of the targeted pulmonary vein by Doppler assessment.

Contact force-sensing catheters. Radiofrequency ablation catheters are now equipped with a pressure sensor at the tip that measures how hard the catheter is pressing on the heart wall.^{26,27} In our experience, this has improved the outcomes of ablation procedures, primarily in persistent atrial fibrillation.²⁸

Three-dimensional cardiac mapping is now universally used for ablation of atrial fibrillation. It uses either electromagnetic data or impedance data to create a real-time 3-dimensional map of the heart (**Figure 7**) and to indicate the position of the ablation catheter. This technology significantly reduces the radiation dose to the patient, as well as the operator.

Complications of ablation

Although catheter ablation for atrial fibrillation is safe, it is still one of the most complex electrophysiologic procedures. Improvements in technology and techniques and accumulated experience over the past 15 years have made ablation safer, especially in tertiary care centers. But adverse outcomes are more frequent in low-volume centers.²⁹

Minor procedural complications include pericarditis, complications at the site of vascular access, and anesthesia-related complications. While they do not affect the long-term




Figure 6. Intracardiac echocardiographic images. A, view with the probe located in the right atrium. B, view during transseptal puncture, routinely performed under intracardiac echocardiographic guidance. AV = aortic valve, LA = left atrium, RA = right atrium, RV = right ventricle, RVOT = right ventricular outflow tract.

outcome for the patient, they may increase hospital length of stay and cause temporary inconvenience.

Major complications include cardiac perforation and tamponade, periprocedural stroke, pulmonary vein stenosis, atrioesophageal fistula, phrenic nerve paralysis, major bleeding, myocardial infarction, and death. In a worldwide survey published in 2005, when atrial fibrillation ablation was still novel, the rate of major complications was 6%.³⁰ By 2010, this had declined to 4.5%,³¹ and the rates of major complications may be significantly lower in more experienced centers.²⁹ In our practice, in 2015, the rate of major complications was 1.3% (unpublished data).

Outcomes of catheter ablation

Clinical outcomes depend on many factors including the type of atrial fibrillation (paroxysmal vs nonparoxysmal), overall health of the atria (atrial size and scarring), patient age and comorbidities, and most importantly, the center's and operator's experience.

In randomized controlled trials comparing ablation and antiarrhythmic drug therapy, the efficacy of ablation in maintaining sinus rhythm has been in the range of 66% to 86% vs 16% to 22% for drug therapy,^{32,33} but these trials have been predominantly in middle-aged white men with paroxysmal atrial fibrillation. These trials also showed that catheter abla-

tion reduced symptoms and improved quality of life. Ablation is less effective in persistent than in paroxysmal atrial fibrillation.³⁴

In a long-term study from our group,¹⁴ 660 (79.4%) of 831 patients who underwent ablation in 2005 were arrhythmia-free and not on antiarrhythmic drug therapy after a total of 1,019 ablations (an average of 1.2 ablations per patient) at a median of 55 months; 125 patients (15%, 41 with more than 1 ablation) continued to have atrial arrhythmia, controlled with drugs in 87 patients (69.6%). Only 38 patients (4.6%) continued to have drug-resistant atrial fibrillation and were treated with rate control with negative dromotropic agents.

Recent evidence

The largest randomized controlled trial of catheter ablation vs drug therapy for atrial fibrillation (Catheter Ablation Versus Antiarrhythmic Drug Therapy for Atrial Fibrillation [CABANA]) was completed recently, and the results were presented at a national meeting, although they have not yet been published in a peer-reviewed journal.³⁵

A total of 2,204 patients with atrial fibrillation (42.4% paroxysmal, 47.3% persistent, and 10.3% long-standing persistent) were randomized to either ablation or drug therapy. Median follow-up was 4 years. The crossover rate was high—9.2% of those randomized to ablation did not undergo it, and 27.5% of those ran-

The procedure can take 3 to 6 hours, depending on the patient's anatomy and the operator's technique




Figure 7. Three-dimensional voltage mapping of the left atrium. Top row, before ablation. Bottom row, after ablation. Voltage is color-coded: pink represents good voltage, red represents very low voltage, and other colors represent other points in the spectrum. LIPV = left inferior pulmonary vein, LSPV = left superior pulmonary vein, RIPV = right inferior pulmonary vein, RSPV = right superior pulmonary vein.

domized to drug therapy underwent ablation.

The incidence of the primary end point (a composite of death, disabling stroke, serious bleeding, and cardiac arrest) was not significantly different between the 2 groups in the inten-

tion-to-treat analysis; however, given the high crossover rates, the as-treated and per-protocol analyses become important, and as-treated and per-protocol analyses revealed a significant benefit of ablation compared with drug therapy. The

hazard ratio (HR) for the primary composite outcome was 0.67 ($P = .006$) on as-treated analysis and 0.73 ($P = .05$) on per-protocol analysis. The HR for all-cause mortality was 0.60 ($P = .005$) on as-treated analysis.

■ PERIPROCEDURAL CONSIDERATIONS

Periprocedural anticoagulation

The risk of thromboembolism is increased during, immediately following, and for several weeks to months after atrial fibrillation ablation.^{36,37}

During the procedure, the risk is related to transseptal sheath placement, electrode catheters in the left atrium, and char formation on ablation catheters. These risks are mitigated with proper and careful sheath and catheter manipulation, maintenance of bubble-free irrigation through lines and sheaths, use of irrigated catheters, and initiation of heparin before transseptal access. Heparin is also infused during the procedure, with close monitoring of activated clotting time.

Postprocedurally, the transiently increased clotting risk could be due to damaged endothelium from the ablation itself and stunning of atrial tissue, which results in impaired contraction. Damaged endothelium improves as the tissue heals, and the stunning resolves by electrical reverse remodeling with sinus rhythm maintenance.

In view of these risks, the referring physician and electrophysiologist must pay careful attention to anticoagulation before and after ablation.

Before the procedure. It is safe to continue anticoagulation uninterrupted through the procedure.^{38,39} If the patient is on warfarin, we want the international normalized ratio to be in the therapeutic range when we perform atrial fibrillation ablation, and the patient takes his or her usual dose on the day of the procedure. If taking a direct oral anticoagulant, patients typically skip a dose the day before ablation and again on the morning of the procedure, and resume taking it immediately afterward while in the anesthesia recovery room.

During the procedure, we start heparin before transseptal puncture, adjust it to achieve an activated clotting time of 300 to 400 seconds, and keep it in this range as long as there are sheaths or catheters in the left atrium.

After the procedure. The current guide-

lines²⁴ recommend that oral anticoagulation be continued without interruption for at least 2 months after the procedure, and in most cases indefinitely, depending on age and comorbidities. The decision to stop anticoagulation after 2 months is typically based on the stroke risk as assessed by the CHA₂DS₂-VASc score (www.chadsvasc.org) and not on the success of the ablation procedure.

■ ANTIARRHYTHMIC DRUGS AFTER THE PROCEDURE

Some patients actually experience more atrial fibrillation in the first weeks to months after the procedure. The mechanism in this setting may be different from that causing the arrhythmia in the first place. The causes of early recurrence of atrial arrhythmias include postablation inflammation, temporary autonomic imbalance, and delay of atrial radiofrequency lesion formation.^{40,41} These arrhythmias may completely resolve as the ablation lesions heal and scars mature.

It has been hypothesized that short-term use of antiarrhythmic drugs after atrial fibrillation ablation is effective in preventing arrhythmias because it alters atrial electrophysiologic characteristics induced by the above transient factors. A recent systematic review of 6 clinical trials showed that short-term use of antiarrhythmic drugs reduces the risk of early arrhythmia recurrence but does not reduce recurrence in the long term.⁴²

In terms of outcomes, any arrhythmias that occur in the first 3 months do not necessarily affect long-term success. This is referred to as the “blinking period.” However, generally speaking, it is preferable to maintain sinus rhythm during that time to avoid further anatomic or electrical left atrial adverse remodeling. In many situations, patients continue taking the same antiarrhythmic agent or start on antiarrhythmic therapy in the first few months after ablation.^{43,44}

The mechanisms of late recurrence of atrial arrhythmias after ablation are thought to be different from those in early recurrence. Late recurrence has been ascribed to incomplete pulmonary vein isolation, recovery of pulmonary vein-left atrium connections, or recovery of any other lines of ablation created in the procedure.^{45,46} For late recurrence of atrial ar-

The safety of ablation has generally improved, especially in tertiary care centers

rhythmia, studies and guidelines suggest that repeat ablation may be an option.^{24,47}

■ PRACTICAL CONSIDERATIONS FOR PROCEDURAL PLANNING

Before the procedure, some electrophysiologists use cardiac computed tomography or magnetic resonance imaging to evaluate the pulmonary vein anatomy. This helps in planning and in selecting the appropriate tools for the procedure.

The patient is asked to fast on the day of

the procedure. The procedure can take 3 to 6 hours, depending on the patient’s anatomy and the operator’s technique and experience. It can be performed with the patient under general anesthesia or conscious sedation. Currently, we use general anesthesia most of the time to maximize patient comfort.

After the procedure, our patients must stay in bed for 4 hours and stay overnight for observation. If no complications arise, they are discharged the next day. ■

■ REFERENCES

1. Go AS. The epidemiology of atrial fibrillation in elderly persons: the tip of the iceberg. *Am J Geriatr Cardiol* 2005; 14(2):56–61. PMID:15785146
2. Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. *JAMA* 2001; 285(18):2370–2375. PMID:11343485
3. Miyasaka Y, Barnes ME, Gersh BJ, et al. Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. *Circulation* 2006; 114(2):119–125. doi:10.1161/CIRCULATIONAHA.105.595140
4. Piccini JP, Hammill BG, Sinner MF, et al. Incidence and prevalence of atrial fibrillation and associated mortality among Medicare beneficiaries, 1993–2007. *Circ Cardiovasc Qual Outcomes* 2012; 5(1):85–93. doi:10.1161/CIRCOUTCOMES.111.962688
5. Moe GK, Rheinboldt WC, Abildskov JA. A computer model of atrial fibrillation. *Am Heart J* 1964; 67:200–220. PMID:14118488
6. Cox JL, Schuessler RB, Boineau JP. The surgical treatment of atrial fibrillation. I. Summary of the current concepts of the mechanisms of atrial flutter and atrial fibrillation. *J Thorac Cardiovasc Surg* 1991; 101(3):402–405. PMID:1999933
7. Cox JL, Schuessler RB, D’Agostino HJ Jr, et al. The surgical treatment of atrial fibrillation. III. Development of a definitive surgical procedure. *J Thorac Cardiovasc Surg* 1991; 101(4):569–583. PMID:2008095
8. Jais P, Haïssaguerre M, Shah DC, et al. A focal source of atrial fibrillation treated by discrete radiofrequency ablation. *Circulation* 1997; 95(3):572–576. PMID:9024141
9. Haïssaguerre M, Jais P, Shah DC, et al. Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. *N Engl J Med* 1998; 339(10):659–666. doi:10.1056/NEJM199809033391003
10. Davies MJ, Pomerance A. Pathology of atrial fibrillation in man. *Br Heart J* 1972; 34(5):520–525. PMID:5031645
11. Wijffels MC, Kirchhof CJ, Dorland R, Allessie MA. Atrial fibrillation begets atrial fibrillation. A study in awake chronically instrumented goats. *Circulation* 1995; 92(7):1954–1968. PMID:7671380
12. Nattel S. New ideas about atrial fibrillation 50 years on. *Nature* 2002; 415(6868):219–226. doi: 10.1038/415219a
13. Medi C, Sparks PB, Morton JB, et al. Pulmonary vein antral isolation for paroxysmal atrial fibrillation: results from long-term follow-up. *J Cardiovasc Electrophysiol* 2011; 22(2):137–141. doi:10.1111/j.1540-8167.2010.01885.x
14. Hussein AA, Saliba WI, Martin DO, et al. Natural history and long-term outcomes of ablated atrial fibrillation. *Circ Arrhythm Electrophysiol* 2011; 4(3):271–278. doi:10.1161/CIRCEP.111.962100
15. Hussein AA, Saliba WI, Barakat A, et al. Radiofrequency ablation of persistent atrial fibrillation: diagnosis-to-ablation time, markers of pathways of atrial remodeling, and outcomes. *Circ Arrhythm Electrophysiol* 2016; 9(1):e003669. doi:10.1161/CIRCEP.115.003669
16. Carlsson J, Miketic S, Windeler J, et al. Randomized trial of rate-control versus rhythm-control in persistent atrial fibrillation: the Strategies of Treatment of Atrial Fibrillation (STAF) study. *J Am Coll Cardiol* 2003; 41(10):1690–1696. PMID:12767648
17. Van Gelder IC, Hagens VE, Bosker HA, et al; Rate Control versus Electrical Cardioversion for Persistent Atrial Fibrillation Study Group. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. *N Engl J Med* 2002; 347(23):1834–1840. doi:10.1056/NEJMoa021375
18. Wyse DG, Waldo AL, DiMarco JP, et al; Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Investigators. A comparison of rate control and rhythm control in patients with atrial fibrillation. *N Engl J Med* 2002; 347(23):1825–1833. doi:10.1056/NEJMoa021328
19. Hagens VE, Crijns HJ, Van Veldhuisen DJ, et al; RAtE Control versus Electrical cardioversion for persistent atrial fibrillation study group. Rate control versus rhythm control for patients with persistent atrial fibrillation with mild to moderate heart failure: results from the RAtE Control versus Electrical cardioversion (RACE) study. *Am Heart J* 2005; 149(6):1106–1111. doi:10.1016/j.ahj.2004.11.030
20. Pedersen OD, Bagger H, Keller N, Marchant B, Køber L, Torp-Pedersen C. Efficacy of dofetilide in the treatment of atrial fibrillation-flutter in patients with reduced left ventricular function: a Danish investigations of arrhythmia and mortality on dofetilide (diamond) substudy. *Circulation* 2001; 104(3):292–296. PMID:11457747
21. Guiot A, Jongnarangsin K, Chugh A, et al. Anticoagulant therapy and risk of cerebrovascular events after catheter ablation of atrial fibrillation in the elderly. *J Cardiovasc Electrophysiol* 2012; 23(1):36–43. doi:10.1111/j.1540-8167.2011.02141.x
22. Oral H, Chugh A, Ozaydin M, et al. Risk of thromboembolic events after percutaneous left atrial radiofrequency ablation of atrial fibrillation. *Circulation* 2006; 114(8):759–765. doi:10.1161/CIRCULATIONAHA.106.641225
23. Themistoclakis S, Corrado A, Marchlinski FE, et al. The risk of thromboembolism and need for oral anticoagulation after successful atrial fibrillation ablation. *J Am Coll Cardiol* 2010; 55(8):735–743. doi:10.1016/j.jacc.2009.11.039
24. Calkins H, Hindricks G, Cappato R, et al. 2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation: executive summary. *J Arrhythm* 2017; 33(5):369–409. doi:10.1016/j.joa.2017.08.001
25. Kuck KH, Brugada J, Fürnkranz A, et al; FIRE AND ICE Investigators. Cryoballoon or radiofrequency ablation for paroxysmal atrial fibrillation. *N Engl J Med* 2016; 374(23):2235–2245. doi:10.1056/NEJMoa1602014
26. Reddy VY, Dukkipati SR, Neuzil P, et al. Randomized, controlled trial of the safety and effectiveness of a contact force-sensing irrigated catheter for ablation of paroxysmal atrial fibrillation: results of the TactiCath Contact Force Ablation Catheter Study for Atrial Fibrillation (TOCCASTAR) Study. *Circulation* 2015; 132(10):907–915. doi:10.1161/CIRCULATIONAHA.114.014092
27. Natale A, Reddy VY, Monir G, et al. Paroxysmal AF catheter ablation with a contact force sensing catheter: results of the prospective,

- multicenter SMART-AF trial. *J Am Coll Cardiol* 2014; 64(7):647–656. doi:10.1016/j.jacc.2014.04.072
28. **Hussein AA, Barakat AF, Saliba W, et al.** Persistent atrial fibrillation ablation with or without contact force sensing. *J Cardiovasc Electrophysiol* 2017; 28(5):483–488. doi:10.1111/jce.13179
 29. **Deshmukh A, Patel NJ, Pant I, et al.** In-hospital complications associated with catheter ablation of atrial fibrillation in the United States between 2000 and 2010: analysis of 93,801 procedures. *Circulation* 2013; 128(19):2104–2112. doi:10.1161/CIRCULATIONAHA.113.003862
 30. **Cappato R, Calkins H, Chen SA, et al.** Worldwide survey on the methods, efficacy, and safety of catheter ablation for human atrial fibrillation. *Circulation* 2005; 111(9):1100–1105. doi:10.1161/01.CIR.0000157153.30978.67
 31. **Cappato R, Calkins H, Chen SA, et al.** Updated worldwide survey on the methods, efficacy, and safety of catheter ablation for human atrial fibrillation. *Circ Arrhythm Electrophysiol* 2010; 3(1):32–38. doi:10.1161/CIRCEP.109.859116
 32. **Wazni OM, Marrouche NF, Martin DO, et al.** Radiofrequency ablation vs antiarrhythmic drugs as first-line treatment of symptomatic atrial fibrillation: a randomized trial. *JAMA* 2005; 293(21):2634–2640. doi:10.1001/jama.293.21.2634
 33. **Jais P, Cauchemez B, Macle L, et al.** Catheter ablation versus antiarrhythmic drugs for atrial fibrillation: the A4 study. *Circulation* 2008; 118(24):2498–2505. doi:10.1161/CIRCULATIONAHA.108.772582
 34. **Brooks AG, Stiles MK, Laborderie J, et al.** Outcomes of long-standing persistent atrial fibrillation ablation: a systematic review. *Heart Rhythm* 2010; 7(6):835–846. doi:10.1016/j.hrthm.2010.01.017
 35. **Packer DL, Lee KL, Mark DB, Robb RA.** Catheter Ablation versus Antiarrhythmic Drug Therapy for Atrial Fibrillation Trial, CABANA. <http://cabanatrial.org/>. Accessed September 10, 2018.
 36. **Scherr D, Sharma K, Dalal D, et al.** Incidence and predictors of periprocedural cerebrovascular accident in patients undergoing catheter ablation of atrial fibrillation. *J Cardiovasc Electrophysiol* 2009; 20(12):1357–1363. doi:10.1111/j.1540-8167.2009.01540.x
 37. **Wazni OM, Rossillo A, Marrouche NF, et al.** Embolic events and char formation during pulmonary vein isolation in patients with atrial fibrillation: impact of different anticoagulation regimens and importance of intracardiac echo imaging. *J Cardiovasc Electrophysiol* 2005; 16(6):576–581. doi:10.1111/j.1540-8167.2005.40480.x
 38. **Hussein AA, Martin DO, Saliba W, et al.** Radiofrequency ablation of atrial fibrillation under therapeutic international normalized ratio: a safe and efficacious periprocedural anticoagulation strategy. *Heart Rhythm* 2009; 6(10):1425–1429. doi:10.1016/j.hrthm.2009.07.007
 39. **Bassiouny M, Saliba W, Rickard J, et al.** Use of dabigatran for periprocedural anticoagulation in patients undergoing catheter ablation for atrial fibrillation. *Circ Arrhythm Electrophysiol* 2013; 6(3):460–466. doi:10.1161/CIRCEP.113.000320
 40. **Koyama T, Tada H, Sekiguchi Y, et al.** Prevention of atrial fibrillation recurrence with corticosteroids after radiofrequency catheter ablation: a randomized controlled trial. *J Am Coll Cardiol* 2010; 56(18):1463–1472. doi:10.1016/j.jacc.2010.04.057
 41. **Oral H, Knight BP, Ozaydin M, et al.** Clinical significance of early recurrences of atrial fibrillation after pulmonary vein isolation. *J Am Coll Cardiol* 2002; 40(1):100–104. pmid:12103262
 42. **Chen W, Liu H, Ling Z, et al.** Efficacy of short-term antiarrhythmic drugs use after catheter ablation of atrial fibrillation—a systematic review with meta-analyses and trial sequential analyses of randomized controlled trials. *PLoS One* 2016; 11(5):e0156121. doi:10.1371/journal.pone.0156121
 43. **Leong-Sit P, Roux JF, Zado E, et al.** Antiarrhythmics after ablation of atrial fibrillation (5A Study): six-month follow-up study. *Circ Arrhythm Electrophysiol* 2011; 4(1):11–14. doi:10.1161/CIRCEP.110.955393
 44. **Roux JF, Zado E, Callans DJ, et al.** Antiarrhythmics after ablation of atrial fibrillation (5A Study). *Circulation* 2009; 120(12):1036–1040. doi:10.1161/CIRCULATIONAHA.108.839639
 45. **Sotomi Y, Inoue K, Ito N, et al.** Cause of very late recurrence of atrial fibrillation or flutter after catheter ablation for atrial fibrillation. *Am J Cardiol* 2013; 111(4):552–556. doi:10.1016/j.amjcard.2012.10.040
 46. **Lee SH, Tai CT, Hsieh MH, et al.** Predictors of early and late recurrence of atrial fibrillation after catheter ablation of paroxysmal atrial fibrillation. *J Interv Card Electrophysiol*. 2004 Jun;10(3):221-6. doi:10.1023/B:JICE.0000026915.02503.92
 47. **Zhang XD, Gu J, Jiang WF, et al.** Optimal rhythm-control strategy for recurrent atrial tachycardia after catheter ablation of persistent atrial fibrillation: a randomized clinical trial. *Eur Heart J* 2014; 35(20):1327–1334. doi:10.1093/eurheartj/ehu017

ADDRESS: Ayman A. Hussein, MD, Cardiac Pacing and Electrophysiology, Department of Cardiovascular Medicine, J2-2, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195; husseia@ccf.org